CD137 is an activating receptor binding to CD137L, expressed on natural killer (NK) cells & T cells, therefore triggering innate & adaptive immunity.
CD137 – CD137L Pathway
TIM-3 – Galectin-9 Pathway
T cell immunoglobulin & mucin-3 (TIM-3; HAVcr-2) is an immune checkpoint receptor involved in the suppression of both innate & adaptive immune cells.
ICOS [CD278] – ICOSL [CD275] Pathway
![ICOS [CD278] – ICOSL [CD275] Pathway](https://www.caltagmedsystems.co.uk/information/wp-content/uploads/icos-600x400px-600x300.png "ICOS [CD278] – ICOSL [CD275] Pathway")
ICOS/ICOSL signalling leads to the activation, proliferation and survival of cytotoxic T cells, as well as the survival of memory T cells.
PD-1 [CD279]/PD-L1 [CD274] Pathway
![PD-1 [CD279]/PD-L1 [CD274] Pathway](https://www.caltagmedsystems.co.uk/information/wp-content/uploads/pd-1-600x400px-600x300.png "PD-1 [CD279]/PD-L1 [CD274] Pathway")
The PD-1/PD-L1 or PD-L2 signalling pathway is a negative regulatory mechanism that inhibits T cell proliferation and cytokine production.
SURAMIN – A Multifunctional Small Molecule with over 100 Years of History
Suramin is a multifunctional molecule with a wide array of potential applications, from parasitic and viral diseases to cancer, snakebite and autism.
Nano Vaccines Induce T Cell Immunity and Control of Tumour Growth
Using nanoparticle technology in making vaccines for infectious diseases/cancer is advancing & enhances the immunogenicity of some vaccine candidates.
Is your drug candidate able to reverse the T Cell Exhaustion-like state in MBL’s in vitro functional screening assay?
The process of T cell exhaustion & how it can be harnessed for immuno-oncology drug discovery and for immune checkpoint screening of drug candidates.
Research Grade Biosimilar Antibodies from ProSci
Therapeutic antibodies dominate pipelines and top selling drugs at major pharmaceutical companies. They have proven to be valuable tools in the fight against diseases from cancer and autoimmune disorders to infectious and neurodegenerative diseases. Beyond therapeutics, monoclonal antibodies shown to
The Dark Side of CAR-T Therapy – Cytokine Release Syndrome (Diaclone)
Immunotherapies such as monoclonal antibodies, bispecific antibodies (Bi-specific T-cell engagers or BiTEs) and adoptive T-cell therapies (e.g. CAR-modified T-cell) have provided great advances in cancer treatment. However, testing new therapies is not without risk. The most common and potentially severe
Innovative Applications of TransFix®
TransFix® is designed for stabilisation of peripheral blood and cerebrospinal fluid to enumerate lymphocyte subpopulations by flow cytometry. However, researchers have developed many new and innovative uses of TransFix. We’ve presented a selection of publications to highlight the versatility of